◎パレクセルがクリニカル・ロジスティックス強化を発表

AsiaNet 56183

共同JBN 0310 （2014.3.20）

【ボストン（米マサチューセッツ州）2014年3月19日PRN=共同JBN】

　＊パレクセル・インターナショナルは、臨床試験サプライをより有効に提供するため、新たな二次包装・ラベリングサービスの世界的能力を強化、追加する。

世界をリードするバイオ医薬品サービス企業、パレクセル・インターナショナル（PAREXEL International Corporation、NASDAQ: PRXL）は19日、世界的な治験ロジスティックスサービス（CLS）を拡大すると発表した。シンガポールに新たに開設した最新の物流センターと米マサチューセッツ州ビレリカの施設をこのほど拡大したことで、パレクセルは顧客の世界的な臨床試験供給要件をより効果的に管理することができるようになる。

パレクセルの治験ロジスティックスサービスは、世界的な臨床試験サプライ、セントラルラボサービス、付属品サプライを同期調整して、安全かつタイムリーな配送を保証する。同社は治験場所への時間内の供給に対するリスク評価・緩和計画とともに世界の輸出入貿易コンプライアンスの専門知識を提供する。新しい能力には二次包装・ラベリングサービスが含まれる。施設の拡大は北米、中南米、アフリカ、アジア地域におけるパレクセルの世界的な治験ロジスティックス基盤の上に構築される。

パレクセルのマーク・A・ゴールドバーグ社長兼最高執行責任者（COO）は「臨床試験の規模と複雑さが増すとともに、クライアントはサプライチェーンとともに一貫した調達、製造、保存、流通プロセスを生み出す戦略を開発し、実行する問題に直面している。当社がこれら重要な流通センターと貯蔵施設に投資することは、生物薬剤のクライアントに高まる世界的サプライ・流通ニーズを支援することによって、その臨床試験処理過程を簡素化する当社の当面の努力の一環である」と語った。

パレクセルのクリニカル・ロジスティクス（http://www.parexel.com/solutions/clinical-research/clinical-logistic-services）施設は、有効期限・更新ラベリングサービスの強化を含む高度な能力を提供する。これらサービスは医薬品メーカーに対する供給品返還の必要をなくし、臨床研究準備期間を短縮し、タイムリーに第1号の患者に対処できる確実な成果を上げることを支援する。その他の能力は、臨床試験サプライを管理し、世界の各地に運ぶ流通、保存のインフラストラクチャー（http:www.parexel.com/solutions/clinical-research）とともに積荷を追跡、監視して在庫レベルを管理する有力なテクノロジーシステムが含まれる。

パレクセルのカート・ノリス副社長（治験ロジスティックスサービス担当）は「パレクセルは調和のとれた設定による保存・流通施設の世界ネットワークの構築を続けて、臨床試験プロセスに必要な資材の一貫して信頼性のある流れを提供する。このことは世界のクライアントに臨床試験資材の最先端管理を提供するという当社コミットメントの表れである」と語った。

▽パレクセル・インターナショナル（PAREXEL International Corporation）について

パレクセル・インターナショナルは世界をリードするバイオ医薬品サービス企業であり、広い領域で知識ベースの委託研究、コンサルティング、医療コミュニケーション・テクノロジーソリューションとサービスを世界の製薬、バイオテクノロジー、医療機器業界に提供している。パレクセルは市場進出時間、ピーク・マーケット・ペネトレーションを促進するソリューションの提供にコミットしおり、医薬品開発と規制コンサルティングから臨床薬理学、臨床試験管理、医療教育、償還までの開発と商品化にわたる重要な専門知識を取得している。パレクセルの子会社であるパレクセル・インフォマティクス（PAREXEL Informatics, Inc.）は、臨床開発プロセスに役立つ画像診断（http://www.parexel.com/solutions/informatics/medical-imaging）を含む最先端テクノロジーソリューションを提供する。米マサチューセッツ州ボストン近郊に本社を置くパレクセルは、世界50カ国の76カ所で活動しており、従業員は1万5100人。パレクセル・インターナショナルについての詳しい情報はwww.parexel.comを参照。

PAREXEL および"Your Journey. Our Mission." は PAREXEL International Corporationと子会社の商標もしくは登録商標である。

▽問い合わせ先

Diana Martin, Vice President, Corporate Communications

PAREXEL International

Tel: +1-781-434-5516

Email: Diana.Martin@PAREXEL.com

Matthew Briggs

PAN Communications

Tel: +1-617-502-4300

Email: PAREXEL@pancomm.com

ソース：PAREXEL International Corporation  

PAREXEL Expands Regional Distribution Center And Supply Depot Network To Enhance Global Clinical Logistics Services

PR56183

BOSTON, Mar. 19, 2014 /PRN=KYODO JBN/ --

    Increases global capacity and adds new secondary packaging and labeling

          services to more efficiently deliver clinical trial supplies

    PAREXEL International Corporation (NASDAQ: PRXL), a leading global

biopharmaceutical services provider, today announced the expansion of its

global Clinical Logistics Services (CLS) capabilities. A new, state-of-the-art

distribution center in Singapore and the recent expansion of the Company's

facilities in Billerica, Mass., will help PAREXEL more effectively manage

clients' global clinical trial supply requirements.

    PAREXEL's Clinical Logistics Services provides synchronized coordination of

clinical trial supplies, central lab services, and ancillary supplies worldwide

to ensure safe and timely distribution. The Company offers risk evaluation and

mitigation planning for in-time-investigational-site supply, as well as

expertise in global import/export compliance. New capabilities include

secondary packaging and labeling services. The facility expansion builds upon

PAREXEL's considerable global clinical logistics infrastructure in North

America, Latin America, Europe, Africa and the Asia/Pacific region.

    "As clinical trials increase in size and complexity, clients are challenged

to develop and implement strategies that create consistent sourcing,

manufacturing, storage and distribution processes along the supply chain," said

Mark A. Goldberg, President and Chief Operating Officer, PAREXEL. "Our

investments in these important distribution centers and depots are part of the

Company's ongoing efforts to simplify the clinical trial journey for

biopharmaceutical clients by supporting their growing global supply and

logistics needs."

    PAREXEL's clinical logistics

(http://www.parexel.com/solutions/clinical-research/clinical-logistic-services)

facilities offer sophisticated capabilities that include enhanced expiry and

update labeling services. These services eliminate the need to return supplies

to the manufacturing organization, reduce study start-up time and help ensure

timely first-patient-in milestones. Additional capabilities include a

distribution and warehousing infrastructure to manage and transport clinical

trial (http://www.parexel.com/solutions/clinical-research) supplies to

locations worldwide, as well as leading technology systems that track and trace

shipments and manage inventory levels.

    "PAREXEL continues to build a global network of storage and distribution

facilities with harmonized configurations that provide a consistent and

reliable flow of materials needed in the clinical trial process," said Kurt

Norris, Corporate Vice President, Clinical Logistics Services, PAREXEL. "This

reflects our commitment to provide leading-edge management of clinical trial

materials to clients across the globe."

    About PAREXEL International

    PAREXEL International Corporation is a leading global biopharmaceutical

services organization, providing a broad range of knowledge-based contract

research, consulting, medical communications, and technology solutions and

services to the worldwide pharmaceutical, biotechnology and medical device

industries. Committed to providing solutions that expedite time-to-market and

peak-market penetration, PAREXEL has developed significant expertise across the

development and commercialization continuum, from drug development and

regulatory consulting to clinical pharmacology, clinical trials management,

medical education and reimbursement. PAREXEL Informatics, Inc., a subsidiary of

PAREXEL, provides advanced technology solutions, including medical imaging

(http://www.parexel.com/solutions/informatics/medical-imaging), to facilitate

the clinical development process. Headquartered near Boston, Massachusetts,

PAREXEL operates in 76 locations in 50 countries around the world, and has

15,100 employees. For more information about PAREXEL International visit

www.PAREXEL.com.

    PAREXEL and "Your Journey. Our Mission." are trademarks or registered

trademarks of PAREXEL International Corporation or its affiliates.

    This release contains "forward-looking" statements regarding future results

and events, including, without limitation, statements regarding expected

financial results, future growth and customer demand. For this purpose, any

statements contained herein that are not statements of historical fact may be

deemed forward-looking statements. Without limiting the foregoing, the words

"believes," "anticipates," "plans," "expects," "intends," "appears,"

"estimates," "projects," "will," "would," "could," "should," "targets," and

similar expressions are also intended to identify forward-looking statements.

The forward-looking statements in this release involve a number of risks and

uncertainties. The Company's actual future results may differ significantly

from the results discussed in the forward-looking statements contained in this

release. Important factors that might cause such a difference include, but are

not limited to, risks associated with: actual operating performance; actual

expense savings and other operating improvements resulting from recent and

anticipated restructurings; the loss, modification, or delay of contracts which

would, among other things, adversely impact the Company's recognition of

revenue included in backlog; the Company's dependence on certain industries and

clients; the Company's ability to win new business, manage growth and costs,

and attract and retain employees; the Company's ability to complete additional

acquisitions, and to integrate newly acquired businesses including the recent

acquisitions of LIQUENT, Inc. and HERON, Inc., or enter into new lines of

business; the impact on the Company's business of government regulation of the

drug, medical device and biotechnology industry; consolidation within the

pharmaceutical industry and competition within the biopharmaceutical services

industry; the potential for significant liability to clients and third parties;

the potential adverse impact of health care reform; and the effects of exchange

rate fluctuations and other international economic, political, and other risks.

Such factors and others are discussed more fully in the section entitled "Risk

Factors" of the Company's Quarterly Report on Form 10-Q for the fiscal quarter

ended December 31, 2013 as filed with the SEC on January 31, 2014, which "Risk

Factors" discussion is incorporated by reference in this press release. The

Company specifically disclaims any obligation to update these forward-looking

statements in the future. These forward-looking statements should not be relied

upon as representing the Company's estimates or views as of any date subsequent

to the date of this press release.

    Contacts:

    Diana Martin, Vice President, Corporate Communications

    PAREXEL International

    Tel: +1-781-434-5516

    Email: Diana.Martin@PAREXEL.com

    Matthew Briggs

    PAN Communications

    Tel: +1-617-502-4300

    Email: PAREXEL@pancomm.com

    SOURCE: PAREXEL International Corporation